120 related articles for article (PubMed ID: 9654108)
1. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors.
Hilger RA; Harstrick A; Eberhardt W; Oberhoff C; Skorzec M; Baumgart J; Seeber S; Scheulen ME
Cancer Chemother Pharmacol; 1998; 42(2):99-104. PubMed ID: 9654108
[TBL] [Abstract][Full Text] [Related]
2. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
Hilger RA; Jacek G; Oberhoff C; Kredtke S; Baumgart J; Seeber S; Scheulen ME
Cancer Chemother Pharmacol; 2000; 45(6):483-8. PubMed ID: 10854136
[TBL] [Abstract][Full Text] [Related]
3. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
Scheulen ME; Hilger RA; Oberhoff C; Casper J; Freund M; Josten KM; Bornhäuser M; Ehninger G; Berdel WE; Baumgart J; Harstrick A; Bojko P; Wolf HH; Schindler AE; Seeber S
Clin Cancer Res; 2000 Nov; 6(11):4209-16. PubMed ID: 11106234
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
Galaup A; Paci A
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):333-47. PubMed ID: 23157726
[TBL] [Abstract][Full Text] [Related]
7. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation.
Główka FK; Łada MK; Grund G; Wachowiak J
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):569-74. PubMed ID: 17210272
[TBL] [Abstract][Full Text] [Related]
8. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
Paci A; Rezai K; Deroussent A; De Valeriola D; Re M; Weill S; Cvitkovic E; Kahatt C; Shah A; Waters S; Weems G; Vassal G; Lokiec F
Drug Metab Dispos; 2006 Nov; 34(11):1918-26. PubMed ID: 16896064
[TBL] [Abstract][Full Text] [Related]
10. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
Meden H; Wittkop Y; Kuhn W
Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
[TBL] [Abstract][Full Text] [Related]
11. Treatment of active secondary progressive multiple sclerosis with treosulfan.
Wiendl H; Kieseier BC; Weissert R; Mylius HA; Pichlmeier U; Hartung HP; Melms A; Kuker W; Weller M
J Neurol; 2007 Jul; 254(7):884-9. PubMed ID: 17446994
[TBL] [Abstract][Full Text] [Related]
12. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.
Koenigsmann M; Mohren M; Jentsch-Ullrich K; Franke A; Becker E; Heim M; Freund M; Casper J
Bone Marrow Transplant; 2004 Sep; 34(6):477-83. PubMed ID: 15286694
[TBL] [Abstract][Full Text] [Related]
13. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
Bojko P; Hilger RA; Ruehm SG; Dirsch O; Seeber S; Scheulen ME
Bone Marrow Transplant; 2003 Mar; 31(6):487-91. PubMed ID: 12665845
[TBL] [Abstract][Full Text] [Related]
14. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Spieth K; Kaufmann R; Gille J
Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
[TBL] [Abstract][Full Text] [Related]
15. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies.
Koyyalamudi SR; Kuzhiumparambil U; Nath CE; Byrne JA; Fraser CJ; O'Brien TA; Earl JW; Shaw PJ
J Chromatogr Sci; 2016 Mar; 54(3):326-33. PubMed ID: 26433392
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.
Danielak D; Twardosz J; Kasprzyk A; Wachowiak J; Kałwak K; Główka F
Eur J Clin Pharmacol; 2018 Jan; 74(1):79-89. PubMed ID: 28975382
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
